OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Relmada expects to initiate its Phase 3 program in the first half of 2026
Poviztra is a second brand of Wegovy
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Subscribe To Our Newsletter & Stay Updated
